Zomedica Corp. (ZOMDF) stock
ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Zomedica r&d expenses
Research and development expenses are spending on new products and technology.
Zomedica's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.65M, down 26.9% year over year. For fiscal 2025 it was $7.17M, down 1.4% from the year before. The highest annual figure on record is $10.35M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.17M | -1.4% |
| FY2024 | Dec 31, 2024 | $7.27M | +26.5% |
| FY2023 | Dec 31, 2023 | $5.74M | +122.8% |
| FY2022 | Dec 31, 2022 | $2.58M | +54.1% |
| FY2021 | Dec 31, 2021 | $1.67M | -79.2% |
| FY2020 | Dec 31, 2020 | $8.04M | -22.2% |
| FY2019 | Dec 31, 2019 | $10.35M | +0.3% |
| FY2018 | Dec 31, 2018 | $10.32M | +275.0% |
| FY2017 | Dec 31, 2017 | $2.75M | +81.2% |
| FY2016 | Dec 31, 2016 | $1.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.07M | -43.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.15M | -37.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.64M | -23.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.78M | -3.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.89M | +25.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.85M | +4.6% |
| Q4 FY2024 | Dec 31, 2024 | $2.15M | -30.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.85M | +112.8% |
| Q2 FY2024 | Jun 30, 2024 | $1.51M | +75.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.77M | +92.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.10M | +347.2% |
| Q3 FY2023 | Sep 30, 2023 | $867.00K | -28.6% |
| Q2 FY2023 | Jun 30, 2023 | $859.00K | +169.3% |
| Q1 FY2023 | Mar 31, 2023 | $918.00K | +161.5% |
| Q4 FY2022 | Dec 31, 2022 | $693.00K | +4.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.22M | +320.4% |
| Q2 FY2022 | Jun 30, 2022 | $319.00K | +17.7% |
| Q1 FY2022 | Mar 31, 2022 | $351.00K | -14.8% |
| Q4 FY2021 | Dec 31, 2021 | $665.00K | -20.7% |
| Q3 FY2021 | Sep 30, 2021 | $289.00K | -89.3% |
| Q2 FY2021 | Jun 30, 2021 | $271.00K | -93.1% |
| Q1 FY2021 | Mar 31, 2021 | $412.00K | -34.6% |
| Q4 FY2020 | Dec 31, 2020 | $838.22K | +6.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.70M | +180.7% |
| Q2 FY2020 | Jun 30, 2020 | $3.91M | +268.2% |
| Q1 FY2020 | Mar 31, 2020 | $630.07K | -91.6% |
| Q4 FY2019 | Dec 31, 2019 | $789.95K | -87.9% |
| Q3 FY2019 | Sep 30, 2019 | $962.46K | +52.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.06M | -58.1% |
| Q1 FY2019 | Mar 31, 2019 | $7.53M | +1154.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.55M | +462.3% |
| Q3 FY2018 | Sep 30, 2018 | $630.37K | +35.4% |
| Q2 FY2018 | Jun 30, 2018 | $2.53M | +402.7% |
| Q1 FY2018 | Mar 31, 2018 | $600.34K | -2.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.17M | – |
| Q3 FY2017 | Sep 30, 2017 | $465.50K | – |
| Q2 FY2017 | Jun 30, 2017 | $504.24K | – |
| Q1 FY2017 | Mar 31, 2017 | $616.45K | – |
See a number that looks wrong?